Olmetec Comp 20 mg / 25 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

olmetec comp 20 mg / 25 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil / hydroklortiazid - tablett, filmdrasjert - 20 mg / 25 mg

Bretaris Genuair Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

bretaris genuair

covis pharma europe b.v. - aclidinium bromide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - bretaris genuair er indikert som en vedlikeholdsbronkodilatorbehandling for å lindre symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kol).

Clopidogrel Acino Pharma GmbH Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom. for ytterligere informasjon, vennligst referer til seksjon 5.

Namuscla Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indikert for symptomatisk behandling av myotonia hos voksne pasienter med ikke-dystrophic myotonic lidelser.

Vanflyta Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Clopidogrel Acino Pharma Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom. for ytterligere informasjon, vennligst referer til seksjon 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Lixiana Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

lixiana

daiichi sankyo europe gmbh - edoxaban tosilate - stroke; venous thromboembolism - antithrombotic agents - forebygging av hjerneslag og systemisk embolism i voksen pasienter med nonvalvular atrieflimmer (nvaf) med én eller flere risikofaktorer, som hjertesvikt, hypertensjon, alder ≥ 75 år, diabetes mellitus, tidligere slag eller forbigående iskemisk angrep ( tia). behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne.

Sevikar 40 mg / 5 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

sevikar 40 mg / 5 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 40 mg / 5 mg

Sevikar 20 mg / 5 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

sevikar 20 mg / 5 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 20 mg / 5 mg